COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin - Sigthorsson, G; Crane, R; Simon, T; Hoover, M; Quan, H; Bolognese, J; Bjarnason, I (Gut, 2000)
Keywords: Adolescent; Adult; Arthritis; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Chromium Radioisotopes - metabolism; COX-2 inhibitor; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors - pharmacology; Disease; Double-Blind Method; Drug dosages; Edetic Acid - metabolism; Family medical history; Female; Gastroesophageal reflux; Humans; indomethacin; Indomethacin - pharmacology; Inflammation; Intestinal Mucosa - drug effects; Intestinal Mucosa - metabolism; intestinal permeability; Isoenzymes - metabolism; Laboratories; Lactones - pharmacology; Male; Medical sciences; Membrane Proteins; Metabolism; Metabolites; non-steroidal anti-inflammatory drugs; Older people; osteoarthritis; Permeability; Pharmacology. Drug treatments; Prostaglandin-Endoperoxide Synthases - metabolism; rofecoxib; Small intestine; Studies; Sulfones; Human; Prostaglandin-endoperoxide synthase; Cell permeability; Enzyme; Treatment efficiency; Antiinflammatory agent; Indometacin; Gut; Cell biology; Enzyme inhibitor; Asymptomatic; Tocolytic; Non steroidal antiinflammatory agent; Placebo; Indoleacetic acid derivatives; Secondary effect; Double blind study; Oxidoreductases; Comparative study